Norway Glp-1 Receptor Agonist Market Size & Outlook
Norway glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Norway glp-1 receptor agonist market highlights
- The Norway glp-1 receptor agonist market generated a revenue of USD 222.9 million in 2023 and is expected to reach USD 1,225.8 million by 2030.
- The Norway market is expected to grow at a CAGR of 27.6% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 222.9 million |
| Market revenue in 2030 | USD 1,225.8 million |
| Growth rate | 27.6% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Norway accounted for 0.6% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 54.96% in 2023. Horizon Databook has segmented the Norway glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
Like other European countries, Norway is witnessing a significant demand for GLP-1 receptor agonists due to the high prevalence of target diseases in the country. According to an article published by NCBI in 2023, diabetes affects approximately 7.5% of the population in Norway, with around 90% of these cases being type 2 diabetes.
Recent advancements, such as the introduction of oral GLP-1 receptor agonists and extended-release formulations, can impact the market by offering increased convenience and adherence benefits, thus propelling overall market growth in Norway.
These developments highlight Norway's increasing impact on GLP-1 receptor agonist, providing novel & effective treatment options and potentially broadening the market as these therapies advance through additional clinical trials and commercialization.
Reasons to subscribe to Norway glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Norway glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Norway GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
